Skyrizi®
Understanding Skyrizi® (risankizumab-rzaa)
Skyrizi® (risankizumab-rzaa) is a targeted biologic therapy used to treat autoimmune diseases by blocking interleukin-23 (IL-23), a key protein that drives inflammation. By inhibiting IL-23, Skyrizi® helps reduce inflammatory responses, alleviating symptoms such as skin plaques, joint pain, and digestive issues associated with various autoimmune conditions.
How Skyrizi® Works:
- Blocks IL-23, a cytokine involved in autoimmune inflammation
- Reduces inflammatory responses, improving skin, joint, and digestive symptoms
- Helps manage chronic autoimmune diseases, offering long-term symptom relief
FDA Approvals:
- Moderate to Severe Plaque Psoriasis: Approved on April 23, 2019
- Psoriatic Arthritis (PsA): Expanded approval on January 21, 2022
- Crohn’s Disease (CD): Expanded approval on June 17, 2022
For more information, please visit the Skyrizi® patient website and speak with your healthcare provider to determine if Skyrizi® is the right treatment option for you.
Referral Form: |
MANUFACTURER: AbbVie Inc. |
CLASS: Interleukin-23 (IL-23) Inhibitor |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: For Plaque Psoriasis & Psoriatic Arthritis Subcutaneous Injection For Crohn’s Disease (IV Infusion + Subcutaneous Injection) |
|
FREQUENCY: For Plaque Psoriasis & Psoriatic Arthritis First two doses: At Week zero and Week four, then every twelve weeks. |
Length of infusion: About 60 mins |
FOR MORE INFORMATION: |
Related drugs
